BIIB Related Analyst PT Change

May 30, 2013 12:49 PM Leerink Swann Raises Biogen (BIIB) Price Target to $271

May 1, 2013 07:20 AM Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List

May 1, 2013 06:45 AM Goldman Sachs Upgrades Amgen (AMGN) to Conviction Buy

Apr 26, 2013 08:03 AM Jefferies Lifts Numbers on Biogen (BIIB) Post Q1

Apr 22, 2013 05:24 PM Deutsche Bank Raises Biogen (BIIB) Price Target to $240

Apr 9, 2013 07:11 AM RBC Capital Raises PT on Biogen (BIIB) to $215

Mar 28, 2013 09:12 AM Biogen (BIIB) Target Raised to $215 at Jefferies after Tecfidera Approved with Favorable Label

Feb 8, 2013 06:53 AM Citi Upgrades Biogen (BIIB) to Buy

Feb 6, 2013 03:50 PM Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal

Jan 3, 2013 06:48 AM Piper Jaffray Downgrades Biogen (BIIB) to Neutral

Sep 27, 2012 07:37 AM Jefferies Lifts Target on Biogen (BIIB) to $176, Hemophilia Data Adds To Valuation

Sep 11, 2012 08:57 AM Cantor Fitzgerald Reiterates a 'Buy' on Sunesis Pharmaceuticals (SNSS); Market Potential for Vosaroxin

Sep 10, 2012 12:55 PM UBS on U.S. Biotechnology - Updating Outlook on Covered Stocks (GILD, AMGN, BIIB, CELG, INCY, IDIX, VRTX, SGEN)

Jul 25, 2012 01:29 PM UBS Maintains a 'Buy' on Biogen (BIIB); Key Takeaways from 2Q12

Jul 25, 2012 10:05 AM Jefferies Maintains a 'Buy' on Biogen (BIIB) on Strong Q2; Adjusting Numbers

May 9, 2012 12:38 PM UBS Maintains a 'Buy' on Biogen (BIIB); Core Franchise Support Valuation; Pipeline Provides Upside Risk

May 2, 2012 02:47 PM Jefferies Increases Price Target in Biogen (BIIB)

May 1, 2012 03:58 PM Baird Maintains a 'Neutral' on Biogen (BIIB); Still Prefer the Sidelines as Pipeline Remains The Focus

Apr 30, 2012 07:13 AM Deutsche Bank maintains a 'Buy' on Biogen Idec (BIIB); Hemophilia Survey Suggests Market Share Gains

Apr 19, 2012 10:38 AM Baird Maintains a 'Neutral' on Biogen (NASDAQ: BIIB); Raising Estimates Ahead of Earnings